AIBG:LSEAIB Group plc Analysis
Data as of 2026-03-10 - not real-time
£792.00
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Price action shows AIB Group trading just above a well‑tested support level, with the 20‑day SMA sitting below the current price and the 50‑day SMA providing a modest upward bias. Technical momentum is modestly positive – the MACD histogram has turned positive and the signal is bullish, while the RSI hovers around the neutral zone, suggesting limited upside pressure but no immediate overbought condition.
The valuation picture is compelling: the trailing P/E sits comfortably below the sector average, and a discounted cash‑flow model places intrinsic value at roughly double the market price, indicating a sizeable margin of safety. The dividend yield is exceptionally high relative to peers, and the payout ratio is moderate, supported by a strong cash position that dwarfs total debt.
Risk considerations include a low beta, reflecting limited price sensitivity to broader market moves, but a relatively high 30‑day volatility and a decreasing volume trend point to potential liquidity constraints. Regulatory exposure is typical for a regional bank operating in Ireland and the UK, with no material news items shifting the risk profile. Overall, the stock appears undervalued with a solid income component, making it attractive for value‑oriented investors who can tolerate short‑term price swings.
The valuation picture is compelling: the trailing P/E sits comfortably below the sector average, and a discounted cash‑flow model places intrinsic value at roughly double the market price, indicating a sizeable margin of safety. The dividend yield is exceptionally high relative to peers, and the payout ratio is moderate, supported by a strong cash position that dwarfs total debt.
Risk considerations include a low beta, reflecting limited price sensitivity to broader market moves, but a relatively high 30‑day volatility and a decreasing volume trend point to potential liquidity constraints. Regulatory exposure is typical for a regional bank operating in Ireland and the UK, with no material news items shifting the risk profile. Overall, the stock appears undervalued with a solid income component, making it attractive for value‑oriented investors who can tolerate short‑term price swings.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near established support with bullish MACD signal
- High dividend yield offering immediate cash return
- Neutral RSI indicating limited short‑term upside
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Significant undervaluation relative to DCF estimate
- Sustainable dividend supporting total return
- Improving operating margins and strong cash generation
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Robust balance sheet with cash far exceeding debt
- Low beta suggesting defensive characteristics
- Value orientation with attractive yield and upside potential
Key Metrics & Analysis
Financial Health
Revenue Growth-11.10%
Profit Margin49.34%
P/E Ratio9.8
ROE14.20%
ROA1.48%
P/B Ratio132.9
Op. Cash Flow£823.0M
Industry P/E17.4
Technical Analysis
TrendNeutral
RSI53.9
Support£730.00
Resistance£818.00
MA 20£767.70
MA 50£795.84
MA 200£693.94
MACDBullish
VolumeDecreasing
Fear & Greed Index78.36
Valuation
Fair Value£1,960.13
GradeUndervalued
TypeValue
Dividend Yield10.63%
Risk Assessment
Beta0.52
Volatility37.60%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.